Globe and MailValeant posts 1Q loss on dermatology deal costsBusinessWeekSales of the antidepressant Wellbutrin XL, blood pressure drug Cardizem CD and pain treatment Ultram ER declined because of generic competition, but dermatology revenue increased and the company reported greater sales in Europe, Latin America, .

Globe and MailAcquisition spree muddies Valeant's financial trajectoryGlobe and MailWellbutrin XL, the antidepressant that was the flagship Biovail product for many years, has seen sales drop sharply as a result of generic competition, Valeant said, while the heart drug Cardizem CD and pain reliever Ultram ER recently lost patent .

Federal Trade Commission v.

FTC suffers another blow in its attack on 'pay-for-delay' settlementsLexology (registration)6 The Sixth Circuit in In re Cardizem CD Antitrust Litigation, 332 F.